EX-99.1
Open exhibit ↗Current Report · Items 8.01, 9.01 · 8-K
Oncotelic Therapeutics, Inc.
OTLCOTCEQUITYCurrent
Other Events
Item 8.01 Other Events. On July 13, 2026, Oncotelic Therapeutics, Inc. (the “ Company ”) presented a corporate presentation (“ Corporate Presentation ”) to its employees, directors and officers and advisors. A copy of the Corporate Presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K. Disclaimer.…
Company context
We are a clinical-stage biopharmaceutical company developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. After the acquisition of Mateon Therapeutics, Inc through a reverse merger in 2019, we realigned the company pipeline to focus on various cancers, including but not limited to rare pediatric cancers. The United States Food and Drug Administration (“FDA”) has granted us Rare Pediatric Designations (“RPD”) for pediatric Diffuse Intrinsic Pontine Glioma (“DIPG”) for OT-101, which was transferred to our joint venture as part of the joint venture agreement (see “JV” below), pediatric melanoma for CAP4 and acute myeloid leukemia (“AML”) for Oxi4503. In addition, the Company, through it’s JV, is developing 5 additional products for treatments of various cancers. Each of the products being developed by the JV has the potential of becoming very successful drugs. The JV is contemplating developing and obtaining regulatory approval for each of the 5 additional products via different regulatory pathways and in various countries and regions. Further, the Company aims to capitalize on a voucher program in the United States (“US”). By focusing on capitalizing on the RPD we anticipate: 1) reducing the cost of clinical development by way of a smaller and faster clinical trial, 2) acceleration of the approval process and final approval, 3) obtaining regulatory/ marketing exclusivity for up to 1
Current securities
Recent company filings
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item
8.01 Other Events.
On
July 13, 2026, Oncotelic Therapeutics, Inc. (the “ Company ”) presented a corporate presentation (“ Corporate
Presentation ”) to its employees, directors and officers and advisors. A copy of the Corporate Presentation is attached as Exhibit
99.1 to this Current Report on Form 8-K.
Disclaimer.
The
information in Section 8.01 of this Current Report on Form 8-K, including the information set forth in 99.1, is being furnished and shall
not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange
Act ”), nor be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange
Act, except as shall be expressly set forth by specific reference in such a filing.